Multiple Sclerosis
Conditions
Brief summary
This is a study aimed to characterize \[18F\]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of \[18F\]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple sclerosis and up to 24 age- and gender- matched healthy volunteers.
Detailed description
Multiple Sclerosis is characterized by brain areas of focal neuroinflammation. Imaging of microglia activation in multiple sclerosis could represent a useful marker of neuroinflammation. A novel PET tracer with high affinity to TSPO, \[18F\]PBR111, is a promising tool for PET imaging of activated microglia. This is a study aimed to characterize \[18F\]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of \[18F\]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple sclerosis and up to 24 age- and gender- matched healthy volunteers. A subgroup of patients and healthy volunteers will be scanned twice in consecutive days, to test the reproducibility of the measure. Another subgroup of patients will be re-scanned with \[18F\]PBR111 after 4-6 months. MRI-based measures will be acquired at baseline and, in those patients with later repeat PET scans, also after 4-6 months. Data from this study will inform about the possible implementation of the \[18F\]PBR111 ligand to monitor the neuroinflammatory process, disease progression, and response to treatment in MS patients.
Interventions
RADIATION[18F]PBR111
radioligand to assess binding to TSPO
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or Female, aged 20-70 2. Able to read, comprehend and record information written in English. 3. Capable of giving written informed consent 4. Provide a venous blood sample that will be used for genetics research and the in vitro ligand binding assay. 5. A female subject is eligible to participate if she is willing to follow contraception guidelines or if she is of non-childbearing potential. 6. Male subjects must agree to use one of the contraception methods MS subjects: 1. Clinical or clinical and laboratory supported diagnosis of multiple sclerosis 2. EDSS score up to and including 7.5 at screening evaluation Healthy Volunteers: 1\. Healthy control subjects defined as free from clinically significant active disease as assessed by the Principal Investigator from their medical and psychiatric past and present history \-
Exclusion criteria
1. If female, positive urine pregnancy test 2. An estimated glomerular filtration rate (eGFR) of less than 60 ml/kg/1.73m2 3. History or presence of a neurological diagnosis 4. Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with radiation exposure. 5. Family history of cancer (one or more first-degree relative diagnosed before the age of 55). 6. Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff. 7. Any subject the investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities or subject's unwillingness to comply with all study-related procedures). 8. Contraindications to MRI scanning 9. Any physical abnormality or functional disability which prevents the subject from acquiring a suitable position for scanning. 10. History of or suffers from claustrophobia or feels that he will be unable to lie still on his back in the PET camera or MRI scanner for a period of at least 90mins. 11. Unwillingness or inability to follow the procedures outlined in the protocol. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VT of [18F]PBR111 | day 30 | Regional VT of \[18F\]PBR111 at baseline in MS patients and age- , gender-, and TSPO binding profile- matched healthy controls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Test-retest variability of regional [18F]PBR111 | 8 months | Test-retest variability of regional \[18F\]PBR111 VT in 2 consecutive days in MS patients and age- ,gender-, and TSPO binding profile- matched healthy controls |
| regional [18F]PBR111 VT | 1.5 years | Change in regional \[18F\]PBR111 VT over \ 4 months after a baseline assessment in MS patients |
| White matter lesion load and distribution | 1.5 years | White matter lesion load (volume of pathological tissue) and distribution as measured by Gadolinium-enhanced and T2-weighted MRI in MS patients |
| Cortical grey matter lesion load and distribution | 1.5 years | Cortical grey matter lesion load and distribution as estimated by the appropriate MRI technique (including high-field MRI in some cases) |
| Genetic polymorphisms related to the TSPO gene | 1.5 years | Genetic polymorphisms related to the TSPO gene and/or genes encoding other proteins which may modulate the binding of ligands to TSPO or TSPO function |
Countries
United Kingdom
Outcome results
None listed